



HAL
open science

DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration

Thibaud Mathis, Florian Baudin, Anne-Sophie Mariet, Sébastien Augustin, Marion Bricout, Lauriane Przegralk, Christophe Roubex, Éric Benzenine, Guillaume Blot, Caroline Nous, et al.

► **To cite this version:**

Thibaud Mathis, Florian Baudin, Anne-Sophie Mariet, Sébastien Augustin, Marion Bricout, et al.. DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration. The Journal of clinical investigation, 2024, 134 (17), pp.e174199. 10.1172/JCI174199 . hal-04667733

HAL Id: hal-04667733

<https://hal.inrae.fr/hal-04667733v1>

Submitted on 5 Aug 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License


DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration

Thibaud Mathis, ... , Stéphane Hunot, Florian Sennlaub

J Clin Invest. 2024. <https://doi.org/10.1172/JCI174199>.

Research In-Press Preview Neuroscience Ophthalmology

Graphical abstract



Find the latest version:

<https://jci.me/174199/pdf>



DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration.

Thibaud Mathis^{1,2,3}, Florian Baudin^{4,5}, Anne-Sophie Mariet⁶, Sébastien Augustin¹, Marion Bricout^{1,2,3}, Lauriane Przegralek¹, Christophe Roubeix¹, Éric Benzenine⁶, Guillaume Blot¹, Caroline Nous¹, Laurent Kodjikian^{2,3}, Martine Mauget-Faÿsse⁷, José-Alain Sahel^{1,7,8}, Robin Plevin⁹, Christina Zeitz¹, Cécile Delarasse¹, Xavier Guillonnet^{1*}, Catherine Creuzot-Garcher^{4*}, Catherine Quantin^{6,10*}, Stéphane Hunot^{11*}, Florian Sennlaub^{1*†}

¹Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012 Paris, France.

²Hopital de la Croix-Rousse, Hospices Civils de Lyon, 103 grande rue de la Croix-Rousse 69004 Lyon, France

³UMR-CNRS 5510, MATEIS, INSA, Université Lyon 1, Campus de la Doua, 69100 Villeurbanne, France

⁴Service d'ophtalmologie, CHU Dijon, 14 rue Paul Gaffarel 21000 Dijon, France

⁵Ramsaysanté, Clinique d'Argonay, 74370 Argonay, France

⁶Service de Biostatistiques et D'Information Médicale (DIM), CHU Dijon Bourgogne, INSERM, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, 14 rue Paul Gaffarel F21000 Dijon, France

⁷Fondation Ophtalmologique Adolphe de Rothschild, 29 rue Manin, F75019 Paris, France

⁸Department of Ophthalmology, University of Pittsburgh school of Medicine, Pittsburgh, PA 15213, United States

⁹Strathclyde Institute for Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK

¹⁰Université Paris-Saclay, UVSQ, INSERM, CESP, 94807 Villejuif, France

¹¹Paris Brain Institute—ICM, Inserm, CNRS, Hôpital de la Pitié Salpêtrière, Sorbonne Université, 75013 Paris

*These authors contributed equally to the work

Conflict of interest statement: The authors have declared that no conflict of interest exists.


†Correspondence should be addressed to the lead contact: Dr Florian Sennlaub, INSERM, UMR_S 968, Institut de la Vision, Paris, F-75012, France. Tel: (33) 1 53 46 26 93,

Email: florian.sennlaub@inserm.fr.

Abstract

Neovascular age-related macular degeneration (nAMD) remains a major cause of visual impairment and puts considerable burden on patients and health care systems. L-DOPA-treated Parkinson's disease (PD) patients have been shown to be partially protected from nAMD, but the mechanism remains unknown. Using murine models, combining 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD and laser-induced nAMD, standard PD treatment of L-DOPA/DOPA-decarboxylase inhibitor, or specific dopamine receptor inhibitors, we here demonstrate that L-DOPA treatment-induced increase of dopamine mediated dopamine receptor D2 (DRD2) signaling inhibits choroidal neovascularization independently of MPTP-associated nigrostriatal pathway lesion. Analyzing a retrospective cohort of more than two hundred thousand nAMD patients receiving anti-VEGF treatment from the French nationwide insurance database, we show that DRD2-agonist treated (PD) patients have a significantly delayed age of onset for nAMD (81.4 (\pm 7.0) vs 79.4 (\pm 8.1) years old, respectively, $p < 0.0001$) and reduced need for anti-VEGF therapies (-0.6 injections per 100 mg/day daily dose of DRD2 agonists the second year of treatment), similar to the L-DOPA treatment. While providing a mechanistic explanation for an intriguing epidemiological observation, our findings suggest that systemic DRD2 agonists might constitute an adjuvant therapy to delay and reduce the need for anti-VEGF therapy in nAMD patients.

Graphical Abstract



Introduction

Alongside Alzheimer's disease, Parkinson's disease (PD) and Age-related macular degeneration (AMD) are the most common age-associated neurodegenerative diseases (1, 2).

AMD is the leading cause of central vision loss in the elderly (3, 4). There are two debilitating late forms of the disease: Geographic atrophy (GA), characterized by an extending lesion of both the retinal pigment epithelium (RPE) and the photoreceptor cell layer, and neovascular AMD (nAMD), defined by leaky choroidal neovascularisation (CNV) that, if untreated, leads to retinal edema, hemorrhage and fibrosis (5, 6). The vascular endothelial growth factor (VEGF) is a critical mediator of the sight-threatening neovascular complication that defines nAMD (7, 8) and its inhibition by frequent intravitreal anti-VEGF therapies reduces the risk of legal blindness in patients by 50% (9). However, the continuous need for repeated intravitreal injections of anti-VEGF therapies puts a considerable burden on patients, ophthalmologists and health care systems (10, 11).

PD is characterized by a progressive, preferential loss of dopaminergic neurons within the *Substantia nigra pars compacta*, resulting in a profound reduction of striatal dopamine which in turn triggers functional changes in the basal ganglia circuitry and hence, cardinal motor symptoms including bradykinesia, stiffness and resting tremor (12, 13). Most newly-diagnosed PD patients are treated with a combination of L-DOPA, a metabolic precursor of dopamine, and a DOPA-decarboxylase inhibitor (DDI) (14). Differing from dopamine, around 5-10% of L-DOPA has the ability to traverse the blood-brain barrier. Once inside, an enzyme known as DOPA-decarboxylase converts it into dopamine, effectively restoring the neurotransmitter levels in the affected brain to alleviate symptoms. To reduce L-DOPA's peripheral conversion into dopamine, and achieve high L-DOPA/dopamine concentrations in the CNS, it is invariably administered in combination with a peripheral DOPA-decarboxylase inhibitor (DDI) that does not cross the blood-brain barrier (15). Yet, despite the administration

of DDI a significant amount of peripheral L-DOPA is converted into dopamine increasing plasmatic dopamine levels by 50-250%, which is responsible for the most common peripheral side-effects of this therapy (nausea, vomiting, orthostatic hypotension) (16–18).

Several epidemiological studies have recently shown that the incidence of PD is significantly increased in individuals treated for nAMD (19–21). This link could be due to the repeated anti-VEGF therapy, or to common risk factors (such as the apolipoprotein epsilon 2 variant (22)) or common neurodegenerative mechanisms (23).

On the other hand one study of retrospective cohorts in large prescription and diagnostic patient databases revealed that patients that were prescribed L-DOPA, were protected against AMD and in particular nAMD (24). The authors had previously shown that L-DOPA inhibits the release of VEGF from RPE mono-cultures *in vitro*, via the orphan receptor GPR143 (25, 26) and proposed that a similar mechanism inhibits nAMD in patients. However, since L-DOPA treatment is invariably administered with a DDI, it also concomitantly leads to an increase in peripheral dopamine levels (18). Moreover, the vast majority of L-DOPA treated patients also have PD. Therefore, any of these factors might be responsible for the epidemiological observation of delay and decrease in nAMD incidence.

Using L-DOPA, DDI, dopamine- agonist and antagonist (i) in murine *in vivo* models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD and laser-induced nAMD (ii) in *ex vivo* choroidal explants, and (iii) in *in vitro* human choroidal endothelial cell cultures, we here investigated the underlying mechanisms of L-DOPA-associated nAMD protection. Our data demonstrated that while MPTP-induced loss of dopaminergic neurons does not directly affect laser-induced CNV, L-DOPA treatment-induced, dopamine-dependent dopamine receptor 2 (DRD2) signaling strongly reduces neovascularization. Mechanistically we demonstrate that dopamine increased the expression of Dual Specificity Phosphatase 4 (DUSP4), a phosphatase known to deactivate mitogen-activated protein (MAP) kinases

involved in angiogenesis. In a retrospective cohort of more than two hundred thousand nAMD patients receiving anti-VEGF treatment of the French nationwide insurance database we further demonstrate that DRD2-agonist treated (PD) patients have a significantly delayed age of onset for nAMD and reduced need for anti-VEGF therapies, similar to the previously reported L-DOPA treatment. Our findings strongly suggest that systemic DRD2 agonists might constitute a much sought after therapy to reduce the need for anti-VEGF therapy in nAMD patients.

Results

L-DOPA/decarboxylase inhibitor treatment prevents choroidal neovascularisation independently of subretinal inflammation and the loss of dopaminergic neurons in mice

A study of retrospective cohorts revealed that nAMD diagnosis is delayed and the frequency of anti-VEGF injections decreased in L-DOPA-treated PD patients (24). However, this could be due to L-DOPA, the co-administered DDI, or the underlying PD pathomechanisms.

To test whether the loss of dopaminergic neurons or its therapy influences choroidal neovascularization (CNV), we submitted C57BL6/J mice to four intraperitoneal (i.p) injections of either a control saline solution or MPTP hydrochloride (20 mg/kg) at 2-h intervals. This MPTP-intoxication regimen reproducibly induces the loss of around 50% of the dopaminergic neurons of the substantia nigra pars compacta (SNpc) as evidenced on tyrosine hydroxylase (TH) immunostained brain sections and the stereological quantification of TH⁺ neurons of the whole SNpc (Fig. 1A and B), mimicking the pathognomic change underlying PD (27–30). After one week, half of the MPTP-mice were treated by daily intraperitoneal PBS, while the other half were injected with L-DOPA and Benserazide, a commonly used DDI (30mg/kg/day and 12mg/kg/day respectively), in exact analogy to therapeutic regimens of PD. Following a week of treatment, the mice underwent subretinal laser-injury, which induces subretinal inflammation and choroidal neovascularization and is commonly used as a model of nAMD (6, 31). RPE/choroidal flatmounts stained for IBA-1+ mononuclear phagocytes (MPs, green) and CD102+vascular endothelial cells (red, Fig. 1C), prepared after an additional seven days of continued treatment, demonstrated that the number of subretinal infiltrating MPs, a driving force of CNV development (6), was not affected by either the MPTP-induced nigrostriatal

lesion, or the L-DOPA/Benserazide treatment (Fig. 1D). However, quantification of the surface covered by CD102⁺CNV revealed that L-DOPA/Benserazide treatment but not the MPTP intoxication induced a significant inhibition of the CNV development (Fig. 1E). This result suggested that L-DOPA/Benserazide treatment and not the dopaminergic pathology induces a reduction in CNV development. Indeed, when we evaluated subretinal IBA1⁺MP infiltration (Fig. 1F and G) and CD102⁺CNV development (Fig. 1H and I) in MPTP-free animals, CNV was significantly inhibited in mice having been pre-treated for seven days and until sacrifice with L-DOPA/Benserazide. This was the case at d4 after laser injury (maximal MP infiltration), d7 (maximal CNV development), and d10 (during CNV involution (31)) (Fig. 1H and 2I). In fact, there were no statistical differences between 4, 7 and 10 days in CNV area for mice treated by L-DOPA/Benserazide, while there was a significant increase between 4 and 7 days and between 7 and 10 days for mice treated by PBS (data not shown). The MP infiltration was not altered by the treatment at any investigated time points. Importantly, the inhibitory effect was only observed in mice treated with both L-DOPA and Benserazide but not in mice treated with the DDI alone.

Taken together, these experiments show that the combined treatment of L-DOPA and Benserazide, but not the MPTP-induced degeneration of dopaminergic neurons, nor the inhibition of the DOPA-decarboxylase inhibits subretinal CNV development. Interestingly, the number of infiltrating MPs was not altered by either the PD model or the treatment at any time point analyzed, in contrast of the proinflammatory effect of MPTP intoxication and L-DOPA treatment in the brain (32, 33).

The decarboxylation of L-DOPA to dopamine is necessary for the anti-angiogenic effect on CNV *ex-vivo* and *in vitro*

Our *in vivo* results demonstrate that PD-associated L-DOPA and Benserazide treatment, but not Benserazide alone, exerts an inhibitory effect on CNV formation, without affecting MP infiltration. The inhibition of CNV *in vivo* could therefore be mediated by L-DOPA, or through Dopamine, which is increased (by 50-250% in patients (18), and up to 200% in animal models (34)) with systemic L-DOPA/Benserazide treatment of PD patients. This is due to the fact that Benserazide only partially prevents the conversion of the high therapeutic doses of L-DOPA to dopamine by the DOPA-decarboxylase (DDC) *in vivo*, likely due to only partial DDC inhibition in peripheral dopaminergic neurons.

In the eye, *Ddc* mRNA expression was detected in the retina, but also in freshly prepared mouse RPE as well as in the RPE/choroid, where it is additionally expressed in sympathetic neurons and mast cells to produce adrenaline and histamine respectively (Fig. 2A). It was also expressed in fresh human RPE (Fig. 2B), in accordance with previous reports of mRNA and protein expression of DDC in the RPE (35). In contrast, *Ddc* mRNA was undetectable in human choroidal endothelial cells (HCECs) compared to RPE (Fig. 2B). Interestingly, dopamine and L-DOPA significantly inhibited vascular sprouting from choroidal explants compared to controls, when administered from day 3 to day 6 (Fig. 2C). Quantifications of the sprouting area, expressed as the increase of sprouting area between 3 and 6 days, revealed a significant inhibition by Dopamine and L-DOPA at 1 μ M, while Benserazide alone had no significant effect (Fig. 2D). Importantly, prior administration of Benserazide (10 μ M) led to much attenuated anti-angiogenic effect of L-DOPA in the choroidal explants (Fig. 2D). These results suggested that preincubation with 10 μ M Benserazide achieved a near complete DDC inhibition and diminished dopamine production in the explants. Indeed, dopamine in turn dose-dependently inhibited vascular sprouting (Fig. 2E). The results from the choroidal explants suggested that

L-DOPA had to be converted to dopamine for its anti-angiogenic effect. Similarly, dopamine significantly inhibited VEGF-induced proliferation of HCECs *in vitro* (Fig. 2E and F). L-DOPA, which can't be metabolized to dopamine in HCEC that lack DDC (Fig. 2B), did not.

A comparison by bulk RNA sequencing of FACS sorted CD31⁺CD11b⁻ endothelial cells from d4 choroidal explants that had or had not been incubated with 1 μM Dopamine from d3 to d4 revealed 13 significantly up-regulated and 9 significantly down-regulated transcripts (Fig. 2H). Among the significantly upregulated transcripts was Dual Specificity Phosphatase 4 (DUSP4), a phosphatase known for deactivating the mitogen-activated protein (MAP) kinases ERK1, ERK2, and JNK (36, 37), all well known for their implication in pro-proliferative VEGF signaling and angiogenesis (38). Indeed, vascular sprouting from *Dusp4*^{-/-} choroidal explants exhibited a significant increase compared to *Dusp4*^{+/+} choroidal explants, thus affirming its role in choroidal endothelial cell proliferation (Fig. 2 I).

Taken together, our data showed that dopamine prevents VEGF-induced HCEC proliferation *in vitro* and dose dependently inhibits CNV *ex vivo*. L-DOPA needs to be converted into dopamine to hold a similar activity, as it had no anti-proliferative impact on DDC-free HCEC cells, and its effect in choroidal explants was inhibited when the DDC was pharmacologically inactivated. Mechanistically, Dopamine increased the expression of the phosphatase DUSP4 in choroidal endothelial cells *ex vivo*, which has been shown to inhibit pro-angiogenic signaling, confirmed by the observation that the vascular sprouting of *Dusp4*^{-/-} choroidal explants was significantly increased compared to controls.

Dopamine receptor 2 activation mediates the CNV inhibition observed under L-DOPA/decarboxylase inhibitor treatment *in vivo*

Dopamine mediates its biological effects through 2 subfamilies of G protein-coupled dopamine receptors: DRD1 and DRD5 (D1-like), and DRD2, DRD3 and DRD4 (D2-like) (39).

All dopamine receptors, except DRD3, are expressed in the retina and the RPE. These receptors mediate a broad range of functions including the dopamine-regulated processes from neurotransmission (DRD5 and DRD4), circadian cycle (DRD2/DRD4), phagocytosis (DRD1) and the regulation of eye growth (balance of DRD5 and DRD4 activation) among others (40–44). Beyond the eye, dopamine receptors are expressed on tumor immune cells and endothelial cells (45–47), but their expression and function in CNV is unknown.

Rt-PCR analysis of mRNA extracts from retina and choroid of control and seven day laser-injured mice confirmed that all dopamine receptors except DRD3 (not detected) were present in retina and choroid (Fig. 3A and B) as previously reported (40, 48, 49). DRD2 mRNA in the RPE/choroid was the only transcript induced by laser-injury, while its expression in the retina and all other DRs remained stable (Fig. 3A and B). DRD2 was also detectable in both, fresh human RPE cells (where it can stem from RPE expression but also ingested rod outer segments) and HCECs, the two major cell types of RPE/choroidal preparations (Fig. 3C). Functionally, the specific DRD2-antagonist Eticlopride completely reversed the anti-angiogenic effect of dopamine on the vascular outgrowth of RPE/choroidal explants (Fig. 3D and E). Moreover, the activation of DRD2 with the specific DRD2 agonist Quinpirole was sufficient to achieve a comparable anti-angiogenic effect to that of dopamine. Yet, activation of DRD1 and 5 (SKF38393) or DRD4 (PD168077) had no such effect (Fig. 3E). *In vivo*, the DRD2-antagonist Eticlopride, also entirely reversed the L-DOPA/DDI-induced inhibition of CD102⁺CNV, quantified on IBA1/CD102 double labeled RPE/choroidal flatmounts of seven-day laser-injured mice (Fig. 3F-H). Most-importantly, the DRD2 agonist Quinpirole, administered in exact analogy to therapeutic regimens of PD (5 mg/kg/day) (50)) achieved a comparable anti-angiogenic effect than the L-DOPA/DDI treatment (Fig. 3G) and none of the administered DR agonists and antagonists significantly altered the number of infiltrating IBA1⁺MPs (Fig. 3H)

Taken together, our data show that blocking the DRD2 receptor prevents the anti-angiogenic effect of dopamine *ex vivo* and the L-DOPA/DDI treatment *in vivo*, demonstrating that L-DOPA/DDI treatment's anti-angiogenic effect requires the activation of DRD2. Importantly, we show that DRD2 activation is sufficient to produce a similar therapeutic response.

The incidence of nAMD and frequency of anti-VEGF injections are reduced in PD patients treated with L-DOPA or DRD2 agonists

A retrospective cohort study from large prescription and diagnostic patient databases revealed that nAMD is delayed in PD patients treated with L-DOPA (24). Due to the relatively low prevalence of PD (1% of subjects older than 60 years) and AMD (3% of subjects older than 70 years for late stage AMD, nAMD or geographic atrophy), even large observational studies are not sufficiently powered to establish the association between AMD, PD and its treatment by L-DOPA and DDIs (1, 2).

To overcome this problem, we data-mined the French national health information database (*Système National des Données de Santé*, SNDS) that contains the information of all treatments, procedures, and diagnostics from the 65 million people treated in France. We first extracted data from nAMD patients registered between January 2008 to December 2016 with a minimum 2-years follow-up after their first intravitreal therapy (IVT) with anti-VEGF, on a database running from 2007 to 2018. nAMD patients were identified as: aged over 50, nAMD disease code on hospitalization discharge or nAMD long-term disease, having nAMD treatment [anti-VEGF IVT, or dynamic phototherapy with verteporfin] in the absence of treatment for other retinal neovascular disease [dexamethasone implant, retinal photocoagulation, etc.]. Other exclusion criteria were high myopia, diagnosis of other retinal diseases, treatments for other macular diseases (dexamethasone implant, retinal photocoagulation, etc.), or other retinal

conditions. The data extracted were age at the first anti-VEGF IVT, sex, diabetic-, hypertensive-dyslipidemia- chronic alcoholism- smoking- and obesity-status, number of IVTs performed in the first year, in the second year and over the first two years, therapeutic class(es) of anti-parkinsonian treatment and anti-emetics. The daily dose of anti-parkinsonian and anti-emetics was calculated from the frequency and dosage of drugs prescribed. Naïve nAMD patients were defined as those naïve of any anti-parkinsonian treatment before their first IVT. During the 9-year period, 202,629 patients were treated for nAMD by anti-VEGF injections (see patients characteristics in Table 1). A total of 9,117 patients were treated with drugs acting directly on the dopaminergic system: of these, 1,570 patients were on L-DOPA/DDI, and 5,650 were treated with DRD2 agonists only (the remaining 1,897 patients were treated with either a combination of L-DOPA/DDI and DRD2 agonists, or other dopaminergic drugs). They were compared to the 193,512 nAMD patients naïve of any dopaminergic treatments, serving as control. Fig. 4A to 4C depicts the number of patients receiving the first IVT as a function of their age in each group.

Our data confirms that patients treated with L-DOPA/DDI were significantly older than control patients when receiving their first anti-VEGF injection for nAMD (Fig. 4D; i.e date of diagnosis of nAMD) (83.3 (\pm 5.6) vs 79.4 (\pm 8.1) years old, respectively, ANOVA p <0.0001). Interestingly, despite lower dosages of DRD2 agonists compared to L-DOPA, patients treated with DRD2 agonists only were also significantly older at first anti-VEGF injection than control patients (Fig. 4D; 81.4 (\pm 7.0) vs 79.4 (\pm 8.1) years old, respectively, ANOVA p <0.0001). Moreover, increasing daily doses of DRD2 agonist were associated with an increase in age at IVT onset, +0.007 year/mg/day (Univariate Generalized Linear Model, p =0.01).

To address the question on the potential influence of an increasing use of L-DOPA/DDI or DRD2 agonists, as the population ages during the study period, we divided our cohort into 3 time periods according to the beginning of anti-VEGF treatment: 2008-2010, 2011-2013, and

2014-2016. As was previously shown (51), we first confirmed an increase in age of the first IVT between the first period (2008-2010), the second period (2011-2013: +0.5 years CI95%[0.41;0.58]), and the third period (2014-2016: +1.88 years CI95%[1.79;1.98]) ($p < 0.0001$, Multivariate Generalized Linear Model, $p < 0.0001$). In the same time, it should be noted that antiparkinsonian drug delivery remained stable over years, as reported on the OpenMedic database, containing information on every drug delivery in France since 2014 (<https://www.data.gouv.fr/en/datasets/open-medic-base-complete-sur-les-depenses-de-medicaments-interregimes/>).

In multivariate analysis (accounting for gender, high blood pressure, diabetes, dyslipidemia, chronic alcoholism, smoking, obesity, IVT initiation period, and other treatment acting indirectly on the dopaminergic system), the positive association with older age at first IVT remained significant in patients treated with L-DOPA/DDI (Multivariate Generalized Linear Model, $p < 0.0001$) or DRD2 agonists (Multivariate Generalized Linear Model, $p < 0.0001$).

Together, these findings suggest later age of first IVT injections in PD patients is independently associated with L-DOPA/DDI treatment or DRD2 agonists. Specifically, it was not due to increase in age at first IVT injections in AMD patients as well as antiparkinsonian drug delivery over years.

Next, we investigated whether L-DOPA/DDI and DRD2 agonists influenced anti-VEGF IVT frequency dose-dependently. We focused our analysis on the second year, as anti-VEGF-naïve nAMD patients are generally initiated with a fixed proactive regimen during the first year, including a 3-monthly loading dose. Therefore, IVT frequency might only truly reflect pathology activity in the second year of treatment. Our data shows that the number of intravitreal anti-VEGF injections needed in the second year decreased by 0.6 injections per 100

mg/day daily dose of DRD2 agonists (Fig. 4E, Univariate Generalized Linear Model, $p<0.0001$). Similarly, the number of intravitreal anti-VEGF injections decreased by 0.13 injections per 100 mg/day of L-DOPA treatment in the second year (Fig. 4F; Univariate Generalized Linear Model, $p=0.02$).

Taken together our data confirms that L-DOPA/DDI therapy delays nAMD onset. Furthermore, we demonstrate that DRD2 agonists delay disease onset similarly. Most importantly, our data shows that both treatments dose-dependently reduce the frequency of anti-VEGF IVTs needed to maintain nAMD stability.

Discussion

An analysis of retrospective cohorts in large prescription and diagnostic patient databases previously revealed that patients prescribed L-DOPA/DDI, in their majority diagnosed for PD, were somewhat protected against AMD and in particular nAMD (24). However, these interesting findings did not determine whether L-DOPA, concomitantly prescribed DDIs, or PD itself was responsible for the observed association.

In mouse, CNV formation can be induced by laser-injury (31) and MPTP intoxication induces the loss of dopaminergic neurons in the *Substantia nigra pars compacta*, mimicking the pathognomic change underlying PD (27–30). Our experiments show that MPTP-induced nigrostriatal pathway injury does not alter a subsequent laser-induced subretinal inflammatory reaction or CNV formation. However, when treated with a combination of L-DOPA and DOPA-decarboxylase inhibitor (DDI), in an exact analogy with PD patients, laser-injured parkinsonian mice exhibited reduced CNV but a similar MP infiltration rate. These results strongly suggest that the PD-associated L-Dopa therapy, and not the loss of central dopaminergic neurons, accounted for the CNV inhibition. Indeed, when mice without MPTP-intoxication were treated with the combinational therapy of L-DOPA/DDI we found the subretinal angiogenesis, but not the MP infiltration, to be similarly inhibited. The DDI alone had no such effect.

L-DOPA is converted to dopamine by the aromatic L-amino acid decarboxylase, which is commonly called the DOPA decarboxylase (DDC) despite the fact that it has a variety of other substrates and is involved in the synthesis of other neurotransmitters and neuromodulators as well as the production of histamine (52). Unlike dopamine, 5-10% of L-DOPA can cross the blood-brain barrier to reach the brain parenchyma where a DOPA-decarboxylase converts it into dopamine. In PD patients, L-DOPA treatment is invariably accompanied by a peripheral DOPA-decarboxylase inhibitor (DDI) (15) to limit peripheral L-DOPA conversion into CNS-

impenetrable dopamine thereby keeping peripheral L-DOPA concentrations at high rate and favoring L-DOPA penetration to the CNS. However, despite the administration of DDI a significant amount of therapeutically administered L-DOPA is converted into dopamine increasing the plasma dopamine levels by 50-250%, which is responsible for most common peripheral side-effects (nausea, vomiting, orthostatic hypotension) (16–18, 34).

In our model, the inhibitory effect of the L-DOPA/DDI treatment could therefore be directly due to L-DOPA itself or to dopamine. Increased dopamine might arise from retinal- (observed in treated PD patients (53)), or choroidal-conversion of L-DOPA to dopamine, additionally to the above described increase in plasma levels. In RPE/choroidal explants, L-DOPA inhibited vascular sprouting only in the presence of DDC activity, which, as we show, is expressed in the RPE/choroid tissue (35). These results demonstrate that L-DOPA needs to be converted into dopamine to display such inhibitory effect *ex vivo*. Accordingly, L-DOPA did not inhibit the VEGF-induced proliferation of HCECs, a cell line that does not express DDC and is therefore unable to convert L-DOPA into dopamine. Dopamine on the other hand, dose dependently inhibited vascular sprouting from choroidal explants and VEGF induced HCEC proliferation. Mechanistically, we showed that dopamine increased the expression of the phosphatase DUSP4 in choroidal endothelial cells and that vascular sprouting of *Dusp4*^{-/-} choroidal explants was significantly increased compared to controls. DUSP4 is well known to deactivate the mitogen-activated protein (MAP) kinases ERK1, ERK2, and JNK (36, 37), all well known for their implication in pro-proliferative VEGF signaling and angiogenesis (38). The dopamine-induced overexpression of DUSP4 might thereby interfere with VEGF signaling and mediate the inhibition of the vascular sprouting.

Taken together these *ex vivo* and *in vitro* data showed that dopamine, and not its precursor L-DOPA, inhibits HCEC proliferation and choroidal angiogenesis. Dopamine exerts its biological effects via dopamine receptors that cannot be activated by L-DOPA (54).

Interestingly, DRD2, which is expressed in HCEC, is the only DR whose expression is increased in laser-induced proliferation of choroidal endothelial cells. Pharmacological blockade of this receptor using the highly specific antagonist Eticlopride (55, 56), completely inhibited the dopamine-dependent anti-angiogenic effect on choroidal vascular sprouting. These results and the observation that a highly selective DRD2 agonist Quinpirole (57, 58), but not other DR-specific agonists, was able to mimic the anti-angiogenic potential of dopamine strongly suggest that DRD2 almost exclusively mediates dopamine anti-angiogenic activity. Although this is, to our knowledge, the first report showing that DRD2 activation potentially mitigates CNV, Quinpirole (a DRD2/3 agonist) and Eticlopride (a DRD2 antagonist) have been shown to inhibit tumoral angiogenesis and to promote neovascularization in dermal wound healing (Basu et al. 2001; Hoepfner et al. 2015; Shome et al. 2011). Indeed, DRD2 activation by dopamine has been shown to inhibit endothelial cell proliferation, as it blocks VEGFR2 phosphorylation and subsequent downstream signaling (45, 46, 60). These observations suggest that it is likely the activation of DRD2 on vascular endothelial cells that inhibits CNV in our models, although we do not exclude that DRD2 activation on RPE cells or subretinal MPs represses the release of angiogenic factors.

Most importantly, when we co-administered the DRD2 antagonist Eticlopride with L-DOPA/DDI in laser-injured mice *in vivo*, we completely abolished the anti-angiogenic effect of the PD treatment. This result confirms that the anti-angiogenic effect of L-DOPA/DDI treatment we observed *in vivo* in experimental mice necessitates the conversion of L-DOPA to dopamine and the activation of the DRD2 receptor.

L-DOPA has been shown to directly activate the receptor GPR143 independently of dopamine and to inhibit VEGF secretion *in vitro* (25, 26). However, in our *ex vivo* choroidal explant model and in laser induced choroidal neovascularisation, this mechanism did not seem

to play a detectable role, as the conversion of L-DOPA to dopamine was necessary for the anti-angiogenic effect.

Taken together, our data showed that dopamine prevents VEGF-induced HCEC proliferation *in vitro* and dose dependently inhibits CNV *ex vivo*. L-DOPA needs to be converted into dopamine to hold a similar activity, as it had no anti-proliferative impact on DDC-free HCEC cells, and its effect in choroidal explants was inhibited when the DDC was pharmacologically inactivated.

Finally, we show that the administration of the DRD2 agonist Quinpirole as a monotherapy was sufficient to significantly inhibit pathogenic subretinal CNV.

In the human disease, our analysis of the national insurance database of more than 200 000 patients treated by anti-VEGF IVT confirm that patients with PD and treated by L-DOPA/DDI, are significantly older at the treatment beginning of nAMD and required less anti-VEGF injections than other patients. Importantly this was also true for DRD2 agonists, a finding that could not specifically be addressed in a previous study (24). Furthermore, we could study the dose-effect of treatment and consider interaction between treatments. Importantly, both treatments, DOPA/DDI and DRD2 agonists dose-dependently reduced the number of anti-VEGF IVTs. It should be noted that anti-VEGF-naive nAMD patients in France are generally initiated with a fixed proactive regimen during the first year and the treatment regimen is only then adapted to pathology activity, explaining why we analyzed only the 2nd year of treatment. The relative low number of injections realized in the second year is in accordance with recent national cohort studies.

Taken together we show that DRD2 agonists increase the age at first IVT by 0.7 years and reduce the IVT frequency by 0,6 injections/year (2nd year) per 100 mg / day of drug taken. Such strong dose dependent effect supports our observations in mouse models where DRD2-specific agonists are highly effective.

We acknowledge several limitations. The results presented in the pharmaco-epidemiological study should be considered in light of the potential confounding factors. Many of them were taken into account in the multivariate analyses and are associated to the occurrence of exudative AMD or PD are known to modulate the dopaminergic system. However, other confounding factors, such as the date of PD diagnosis, cannot be obtained in the database. Moreover, there can be an unexpected association between reduced ophthalmological care utilization in patients with advanced PD. We accounted for this by focusing on patients treated with monotherapy with dopaminergic agonists or L-DOPA, which constitute the first-line treatment for Parkinson's disease. These patients received, on average, moderate doses, indicative of early-stage disease. While a marginal delay in treatment initiation due to Parkinson's disease-related care access challenges might explain a slight shift in the timing of the first injection or injection frequency, it does not explain a delay of several years for a condition necessitating urgent and singular anti-VEGF treatment.

In general, it is important to note that the health insurance databases, such as the SNDS, are administrative database that contain a limited amount of information for each patient (disease codes, consumption of care, but not disease onset or disease severity). Therefore, case identification was based on treatment delivery and correct coding of hospitalizations and long-term diseases. Compared to retrospective clinical studies based on patient's hospital files the available information is therefore limited. On the other hand, pharmaco-epidemiological studies, due to their nationwide nature and great number of patients, are sufficiently powered to detect associations of diseases and treatments that are otherwise difficult to detect. Here, we combined the pharmaco-epidemiological study with animal models that closely mimic the diseases to evaluate the plausibility of the associations and possible causalities.

Together, our experimental and epidemiological work strongly suggest that L-DOPA treatment, and not PD disease or concomitant DDI therapy reduces the need of anti-VEGF IVTs

in nAMD patients. Furthermore, our data demonstrates that L-DOPA exerts its protective effect via DRD2 activation following DDC-dependent conversion into dopamine in animal models, and that DRD2 activation in patients similarly reduces IVT burden in nAMD patients. Preventive systemic administration of DRD2 agonists have the potential to delay the progression of high-risk intermediate AMD patients to nAMD and to reduce their continuous need for repeated intravitreal anti-VEGF injections.

Materials and methods

Sex as a biological variable

Male mice were used to minimize variations in angiogenesis due to reproductive hormonal changes observed in females.

Animals

Wild-type (C57BL/6J) male mice were obtained from Janvier Labs (Le Genest Saint Isle, France). *Dusp4*^{-/-} mice were generated as outlined in the original paper by the co-author Pr Plevin (61). They were kept under specific pathogen-free condition in a 12-h light/dark cycle and had access to food and water *ad libitum*. Upon arrival, mice were acclimated for at least 1 week before any experimentation.

Chemicals/treatments

MPTP hydrochloride, L-3,4-dihydroxyphenylalanine methyl ester and Benserazide hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dopamine, Quinpirole, SKF38393, PD168077 and Eticlopride were purchased from Tocris Bioscience (Bristol, UK). Human recombinant VEGF165 was purchased from R&D Systems (Minneapolis, MN, USA).

MPTP model

For all experiments, the acute MPTP model was used as previously described (30). Briefly, male mice received 4 intraperitoneal (i.p) injections of either a control saline solution or MPTP hydrochloride (20 mg/kg, Sigma-Aldrich, Saint-Louis, MO, USA) at 2-h intervals and were kept for 48-h at 28°C before returning to 22°C for the rest of the experiment. MPTP intoxication resulted in mortality rates between 10-30%. TH-positive neurons were quantified stereologically using the VisioScan stereology tool on regularly spaced 20- μ m thick sections

covering the whole substantia nigra pars compacta (SNpc). The SNpc was delineated (62), and TH-positive cell bodies were counted by bright-field microscopy, using a Leitz microscope equipped with Mercator image analysis software (ExploraNova, La Rochelle, France).

Laser injury model

Eight-weeks-old male mice were anesthetized with i.p injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). After pupil dilation, laser coagulations were performed with a 532-nm ophthalmological laser Yag Eyelite (Vitra Laser, Alcon, Rueil-Malmaison, France) mounted on an operating microscope. Four impacts per eye were performed for immunochemistry assays and 10 to 12 impacts per eye were performed for qPCR assays (450 mW, 50 ms and 250 μ m). One week prior to the laser injury and until sacrifice, the mice were treated with daily intraperitoneal injections of PBS (control), L-DOPA (30mg/kg/day) /Benserazide (12 mg/kg/day) (28, 63), Quinpirole (5 mg/kg/day) (50) or Eticlopride (1 mg/kg/day) (64, 65). The concentrations used in mice closely matched the concentrations used in the clinic.

Immunohistochemistry and histology

After fixation in a 4% paraformaldehyde solution, the retinas and choroids were incubated with anti-IBA-1 (1:400, #019-19741, FUJIFILM Wako, Osaka, Japan) and anti-CD102 (for laser-experiments only; 1:200, #553325, BD Biosciences Pharmingen, San Diego, CA, United States) in PBS containing 0.1% Triton X-100 overnight at room temperature with gentle rocking. After few washes in PBS, samples were incubated for 2 hours at room temperature with appropriate Alexa Fluor® conjugated secondary antibodies (1:500, Thermo Fisher Scientific, Waltham, MA, USA) in PBS solution and were counterstained with Hoechst (1:1000, #33258, Thermo Fisher Scientific). Preparations were rinsed, mounted on glass slides with Fluoromount aqueous mounting medium (Sigma-Aldrich). Preparations were observed under a fluorescence microscope (DM5500, Leica, Wetzlar, Germany) and the surface covered

by CD102+CNV was measured on photographs and the average CNV size was calculated; IBA-1+ MPs on the RPE were counted in a diameter of 500µm around the CD102+ neovascularisations; IBA-1+ cells were counted on whole RPE/choroidal flat-mounts and on the outer segment side of the retina.

Deeply anesthetized mice were perfused with PBS, followed by 100 ml of paraformaldehyde 4% to fix the brain tissue. The brains were dissected and stained with monoclonal anti-mouse Tyrosine Hydroxylase (1:200, #22941, Immunostar, Hudson, WI, USA).

Reverse transcription and real-time polymerase chain reaction (RT-PCR)

Total RNA was isolated with Nucleospin RNAII (Macherey-Nagel, Düren, Germany). RNA yields were then measured at 260 nm using the NanoDrop™ 8000 spectrophotometer (Thermo Fisher Scientific). Single-strand cDNA was synthesized using 1 µg of total total RNA pretreated with DNase amplification grade, oligo-dT as primer and superscript II reverse transcriptase (Thermo Fisher Scientific). RT-PCR was realized by the StepOne Plus real-time PCR system (Applied Biosystems, Waltham, MA, USA), using 1/100 of cDNA incubated with the polymerase and the appropriate amounts of nucleotides (PowerSYBR Green PCR mix, Applied Biosystems). PCR reactions were performed in 45 cycles of 15 s at 95°C and 45 s at 60°C. Results were normalized by expression of Actine2 or RPS26. Primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA USA) and sequences are available upon request.

Vascular sprouting from choroid *ex vivo*

Experiments were performed as previously described (66, 67). Eyes were enucleated from two weeks-old C57BL/6J pups and Dusp4^{-/-} mice (61) and kept in ice-cold Opti-MEM Reduced Serum Media (Opti-MEM) (Invitrogen, Cergy Pontoise, France) before dissection. The choroid-scleral complex was separated from the other eye tissues and cut into approximately 1

mm×1 mm. Choroid/sclera fragments were placed in growth factor-reduced phenol red free matrigel (Corning, Boulogne Billancourt, France) seeded in 96 well plates.

Choroid/sclera fragments were then cultured for 3 days in Endothelial Cell Growth Media 2 (ECGM-2) (Promocell GmbH, Heidelberg, Germany) supplemented with 1% penicillin/streptomycin in a 37°C cell culture incubator. On day 3, Choroid fragments were treated with specific molecules as described from day 3 until day 6 of culture. Photos of individual explants were taken and the areas of sprouting out of the explant were quantified with Image J software (National Institute of Health, Bethesda, Maryland, USA) at day 3 and day 6. The surface of each individual choroidal explant and pre-incubation sprouts at day 3 was subtracted from the surface at day 6 and divided by the pre-incubation sprouts at day 3 to calculate the vascular sprouting that occurred in the presence or absence of specific treatment as a fold of d3 sprouting.

RNAseq analysis of choroidal endothelial cells from dopamine stimulated choroidal explants

Choroid/sclera fragments were cultured as described above. On day 3, Choroid fragments were treated with 1 μ M dopamine and kept in culture for an additional 24h. On day 4, choroidal explants were dissociated with collagenase, and CD31+CD11b- cells were sorted on a FACSMELODY cell sorter (BD Biosciences, Franklin Lakes, NJ, USA). Cells were immediately flash frozen in 96 well plates until further processing. RNAseq Libraries were made from 500 sorted endothelial cells using SMART-Seq v4 Ultra Low Input RNA Kit (Takara bio Inc., Kusatsu, Japan). RNAseq libraires were sequenced on a NovaseqX illumina sequencer (iGENseq, ICM, Paris). Fastq files were trimmed using Trimmomatic v0.39 using the NexteraPE-PE adapter file. The paired reads were then aligned using STAR (v2.7.9a) against the mouse reference genome from Ensembl v106 (generated 2022/06/21), with option "--quantMode GeneCounts". All count files were concatenated into a single file and a sample

file including the conditions and the replicate numbers was generated. The count file and the sample file were loaded in EYE.DVseq, an in-house R Shiny application. 1 was added to all counts and the genes having a total count < 10 across all samples were removed. DESeq2 (v1.40.2) analysis was performed comparing the CONTROL and dopamine conditions. The results were then filtered for significant genes using the p-values (< 0,05).

Cell proliferation assay

4000 HCECs (#36052-03, Celprogen, Torrance, CA, USA) were seeded in a 24-well plate pre-coated by Gelatine, cultured for 24h in ECGM-2, serum-starved for 24h in Opti-MEM, and then treated with either PBS, dopamine or L-DOPA, followed 10 minutes later by addition of 10 ng/ml VEGF. After culture for 24h, cells were fixed by 4% paraformaldehyde, nuclei were stained with Hoechst and automatically counted under fluorescent microscope (Arrayscan VTI HCS Reader, Thermo Fisher Scientific).

Clinical cohort

The French national health information database (Système National des Données de Santé, SNDS) was used. This database collects all the reimbursement information for the entire French population in terms of medical and surgical procedures carried out, treatments provided, hospital admissions and their reasons, and long-term conditions giving entitlement to additional reimbursements. The study presented here is part of the French Epidemiology and Safety (EPISAFE) collaborative program (68). We designed an algorithm for identifying nAMD patients, aged 50 years and older. Identification criteria were nAMD diagnosis, nAMD long-disease code, or reimbursement of nAMD treatments (anti-VEGF intravitreal injection, or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, treatments for other macular diseases (dexamethasone implant, retinal photocoagulation, etc.), or other retinal conditions. Included nAMD patient needed to have had

a minimum 2-years follow-up after their first IVT. The data extracted were age at the first anti-VEGF IVT, sex, diabetic, chronic alcoholism, smoking, obesity, hypertensive and dyslipidemia status, number of IVTs performed in the first year, in the second year and over the first two years, therapeutic class(es) of anti-parkinsonian treatment used and anti-emetics deliveries. The daily dose of anti-parkinsonian treatment was approximated by the treatment packaging, the number of mg per presentation and the frequency of dispensing. Naïve nAMD patients were defined as those naïve of any IVT anti-parkinsonian treatment before first IVT. Comparisons were made using the chi-squared test for categorical variables and the signed-rank test for continuous variables. Generalized linear model were computed. Statistical significance was set at $P < .05$ (two-tailed tests). All data processing and statistical analyses were performed using the SAS statistical analysis software package (SAS Enterprise Guide® version 7.1; SAS Institute, Inc., Cary, NC, USA).

Statistical Analysis

For pharmacoepidemiological data the statistical methods are described above. For in vivo and in vitro experiments Graph Pad 7 (GraphPad Software) was used for data analysis. All values are reported in the the scatter dot blots as well as the mean +/- SEM. Statistical analysis and variance analysis was performed by one-way ANOVA, corrected by Bonferroni post-test for multiple comparison, or Mann-Whitney U-test for two-group comparison depending on the experimental design.

Study approval

All animal experimental protocols and procedures adhered to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the French Ministry of Higher Education, Research and Innovation (APAFIS authorization #18912 2019011417393998).

The clinical study was approved by the French Institute of Health Data (registration number 115306, 01/24/2019) and by the French Data Protection Authority (registration number D.R. 2019-100, 04/12/2019). This study adhered to the tenets of the Declaration of Helsinki.

Data availability

Experimental materials are available upon request with no restrictions. The RNA-Seq raw fastq files and count files were deposited in the NCBI's Gene Expression Omnibus database (GSE266525). The database used in the clinical study was transmitted by the French National Health Insurance Fund (Caisse nationale de l'assurance maladie CNAM), which is responsible for the extraction of SNDS data. The use of these data by our department was approved by the National Committee for data protection. We are not authorized to transmit this data. Data are available for researchers who meet the criteria for access to these French data from the CNAM: training that open a personal accreditation, and approval of the protocol by required authorities (Ethical and scientific committee for research, studies and evaluations in the health field-CESREES, and National Committee for data protection-CNIL). A Supporting Data Values file is available online as supplemental material.

Author contributions

Conceptualization: TM, CCG, CQ, SH, and FS

Data curation: TM, CCG, CQ, SH, and FS

Funding acquisition: CCG, CQ, SH, JAS and FS

Data collection: TM, FB, ASM, SA, MB, LP, CR, EB, GB, CN, CCG, CQ, CD, XG, SH, and FS

Methodology: CD, FB, ASM, EB, CQ, SH, and FS

Resources: RP, CZ, JAS, CCG, CQ, SH, and FS

Supervision: CD, XG, CCG, CQ, SH, and FS

Writing – original draft: TM, CCG, CQ, SH, and FS reviewed and edited by TM, FB, SH, and FS

Acknowledgments:

We thank the Imaging Core Facility, the Phénotypage Cellulaire et Tissulaire platform, and the animal facility of the Institut de la Vision, as well as the PHENO-ICMice facility supported by (ANR-10-IAIHU-06 and ANR-11-INBS-0011-NeurATRIS), and the “Fondation pour la Recherche Médicale”. This work was supported by grants from INSERM, ANR KEVINplus (ANR-22-CE14-0015-01); ANR MACLEAR (ANR-15-CE14-0015-01), LABEX LIFESENSES [ANR-10-LABX-65] supported by the ANR (Programme d’Investissements d’Avenir [ANR-11-IDEX-0004-02]), IHU FOReSIGHT [ANR-18-IAHU-0001] supported by French state funds managed by the Agence Nationale de la Recherche within the Investissements d’Avenir program, Carnot, and the Association de Prévoyance Santé de ALLIANZ.

References

1. de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. *Lancet Neurol*. 2006;5(6):525–535.
2. Colijn JM, et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. *Ophthalmology*. 2017;124(12):1753–1763.
3. Wong WL, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):e106-116.
4. Klein R, et al. The epidemiology of age-related macular degeneration. *Am J Ophthalmol*. 2004;137(3):486–495.
5. Sarks SH. Ageing and degeneration in the macular region: a clinico-pathological study. *Br J Ophthalmol*. 1976;60(5):324–341.
6. Guillonneau X, et al. On phagocytes and macular degeneration. *Prog Retin Eye Res*. 2017;61:98–128.
7. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. *Invest Ophthalmol Vis Sci*. 1994;35(12):3974–3979.
8. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355(14):1419–1431.
9. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. *Am J Ophthalmol*. 2012;153(2):209-213.e2.

10. Rofagha S, et al. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP). *Ophthalmology*. 2013;120(11):2292–2299.
11. Baek SK, et al. Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment. *Sci Rep*. 2019;9(1):1–10.
12. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. *Mov Disord Off J Mov Disord Soc*. 2013;28(1):24–30.
13. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. *Annu Rev Neurosci*. 1999;22:123–144.
14. Kobylecki C. Update on the diagnosis and management of Parkinson's disease. *Clin Med Lond Engl*. 2020;20(4):393–398.
15. Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson's Disease: Current Status and Future Developments. *Curr Neuropharmacol*. 2018;16(8):1239–1252.
16. Dutton J, et al. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. *Clin Chem*. 1993;39(4):629–634.
17. Schneider F, et al. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. *Br J Clin Pharmacol*. 2018;84(10):2422–2432.

18. Ceballos-Baumann AO, et al. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients. *J Neurol.* 1990;237(1):24–28.
19. Chung S-D, et al. Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study. *Am J Ophthalmol.* 2014;157(2):464-469.e1.
20. Etminan M, Samii A, He B. Risk of Parkinson’s disease in patients with neovascular age-related macular degeneration. *J Curr Ophthalmol.* 2018;30(4):365–367.
21. Choi S, et al. Association of Age-Related Macular Degeneration on Alzheimer or Parkinson Disease: A Retrospective Cohort Study. *Am J Ophthalmol.* 2020;210:41–47.
22. McKay GJ, et al. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. *Hum Mutat.* 2011;32(12):1407–1416.
23. Huang X, Chen PC, Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. *Neurology.* 2004;62(12):2198–2202.
24. Brilliant MH, et al. Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. *Am J Med.* 2016;129(3):292–298.
25. Lopez VM, et al. L-DOPA is an endogenous ligand for OA1. *PLoS Biol.* 2008;6(9):e236.
26. Falk T, et al. PEDF and VEGF-A Output from Human Retinal Pigment Epithelial Cells Grown on Novel Microcarriers. *J Biomed Biotechnol.* 2012;2012.
<https://doi.org/10.1155/2012/278932>.

27. Przedborski S, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. *J Neurochem*. 2001;76(5):1265–1274.
28. Lundblad M, et al. Pharmacological validation of a mouse model of 1-DOPA-induced dyskinesia. *Exp Neurol*. 2005;194(1):66–75.
29. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. *Br J Pharmacol*. 2011;164(4):1357–1391.
30. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. *Nat Protoc*. 2007;2(1):141–151.
31. Lavalette S, et al. Interleukin-1 β inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration. *Am J Pathol*. 2011;178(5):2416–2423.
32. Troncoso-Escudero P, et al. Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease. *Front Neurol*. 2018;9:860.
33. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? *Lancet Neurol*. 2009;8(4):382–397.
34. Rose S, Jenner P, Marsden CD. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. *Mov Disord Off J Mov Disord Soc*. 1988;3(2):117–125.
35. Ming M, et al. Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease. *J Transl Med*. 2009;7:53.

36. Cagnol S, Rivard N. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. *Oncogene*. 2013;32(5):564–576.
37. Echavarria R, Hussain SNA. Regulation of angiotensin-1/Tie-2 receptor signaling in endothelial cells by dual-specificity phosphatases 1, 4, and 5. *J Am Heart Assoc*. 2013;2(6):e000571.
38. Zachary I, Glick G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. *Cardiovasc Res*. 2001;49(3):568–581.
39. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. *J Recept Signal Transduct Res*. 2004;24(3):165–205.
40. Nguyen-Legros J, Versaux-Botteri C, Vernier P. Dopamine receptor localization in the mammalian retina. *Mol Neurobiol*. 1999;19(3):181–204.
41. Witkovsky P. Dopamine and retinal function. *Doc Ophthalmol Adv Ophthalmol*. 2004;108(1):17–40.
42. Ko GY-P. Circadian regulation in the retina: From molecules to network. *Eur J Neurosci*. 2020;51(1):194–216.
43. Zhou X, et al. Dopamine signaling and myopia development: What are the key challenges. *Prog Retin Eye Res*. 2017;61:60–71.
44. Feldkaemper M, Schaeffel F. An updated view on the role of dopamine in myopia. *Exp Eye Res*. 2013;114:106–119.

45. Basu S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. *Nat Med.* 2001;7(5):569–574.
46. Sarkar C, et al. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. *Am J Physiol Heart Circ Physiol.* 2004;287(4):H1554-1560.
47. Chakroborty D, et al. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. *Clin Cancer Res Off J Am Assoc Cancer Res.* 2004;10(13):4349–4356.
48. Derouiche A, Asan E. The dopamine D2 receptor subfamily in rat retina: ultrastructural immunogold and in situ hybridization studies. *Eur J Neurosci.* 1999;11(4):1391–1402.
49. Jackson CR, et al. Essential roles of dopamine D4 receptors and the type 1 adenylyl cyclase in photic control of cyclic AMP in photoreceptor cells. *J Neurochem.* 2009;109(1):148–157.
50. Thompson D, Martini L, Whistler JL. Altered Ratio of D1 and D2 Dopamine Receptors in Mouse Striatum Is Associated with Behavioral Sensitization to Cocaine. *PLoS ONE.* 2010;5(6):e11038.
51. Creuzot-Garcher CP, et al. Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study. *Ophthalmol Sci.* 2022;2(1):100114.
52. Sanchez-Jiménez F, et al. Structural and functional analogies and differences between histidine decarboxylase and aromatic l-amino acid decarboxylase molecular networks: Biomedical implications. *Pharmacol Res.* 2016;114:90–102.

53. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. *Invest Ophthalmol Vis Sci.* 1990;31(11):2473–2475.
54. Misu Y, et al. Neurobiology of L-DOPAergic systems. *Prog Neurobiol.* 1996;49(5):415–454.
55. Martelle JL, Nader MA. A Review of the Discovery, Pharmacological Characterization, and Behavioral Effects of the Dopamine D2-Like Receptor Antagonist Eticlopride. *CNS Neurosci Ther.* 2008;14(3):248–262.
56. Seeman P, Ulpian C. Dopamine D1 and D2 receptor selectivities of agonists and antagonists. *Adv Exp Med Biol.* 1988;235:55–63.
57. Malo M, et al. Selective pharmacophore models of dopamine D(1) and D(2) full agonists based on extended pharmacophore features. *ChemMedChem.* 2010;5(2):232–246.
58. Seeman P, Schaus JM. Dopamine receptors labelled by [3H]quinpirole. *Eur J Pharmacol.* 1991;203(1):105–109.
59. Shome S, et al. Dopamine regulates angiogenesis in normal dermal wound tissues. *PLoS One.* 2011;6(9):e25215.
60. Sinha S, et al. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. *J Cell Sci.* 2009;122(Pt 18):3385–3392.
61. Lawan A, et al. Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. *J Biol Chem.* 2011;286(15):12933–12943.

62. German DC, et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. *Neurodegener J Neurodegener Disord Neuroprotection Neuroregeneration*. 1996;5(4):299–312.
63. Cenci MA, Ohlin KE. Rodent models of treatment-induced motor complications in Parkinson's disease. *Parkinsonism Relat Disord*. 2009;15 Suppl 4:S13-17.
64. Ferrari F, Giuliani D. Effects of (-)eticlopride and 7-OH-DPAT on the tail-suspension test in mice. *J Psychopharmacol Oxf Engl*. 1997;11(4):339–344.
65. Chausmer AL, Katz JL. The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. *Psychopharmacology (Berl)*. 2001;155(1):69–77.
66. Shao Z, et al. Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis. *PLOS ONE*. 2013;8(7):e69552.
67. Montassar F, et al. Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2017;31(3):1107–1119.
68. Daien V, et al. French Medical-Administrative Database for Epidemiology and Safety in Ophthalmology (EPISAFE): The EPISAFE Collaboration Program in Cataract Surgery. *Ophthalmic Res*. 2017;58(2):67–73.

Figure Legends




Fig. 1: L-DOPA/decarboxylase inhibitor treatment prevents choroidal neovascularization independently of subretinal inflammation and the loss of central dopaminergic neurons in mice

A and B. Tyrosine hydroxylase (TH) stained substantia nigra pars compacta (SNpc) (A) and quantification of dopaminergic TH⁺ neurons in the SNpc (B) of 9-week-old C57BL/6J mice that received PBS or MPTP intoxication at 6-weeks of age and laser-injury at 8-weeks and were treated by intraperitoneal PBS or L-DOPA (30mg/kg/day) + Benserazide (12mg/kg/day) starting one week before the injury until seven days post laser injury. One-way ANOVA/Bonferroni test; p-values indicated in the figure.

C - E. IBA-1- (green) and CD102- (red) stained choroidal flatmounts (C), quantification of the number of subretinal IBA-1⁺ mononuclear phagocytes counted on the RPE at a distance of 0-500µm to CD102⁺ CNV (D), and quantification of CD102⁺ CNV area (E), 7 days after laser injury of mice that received MPTP intoxication and treatment regimens as for (A). One-way ANOVA/Bonferroni test; p-values indicated in the figure, CTL-PBS versus MPTP-PBS *P*=non-significant.

F. IBA-1- (green) and CD102- (red) stained choroidal flatmounts 7 days after laser injury of 8-week-old C57BL/6J mice treated by PBS, Benserazide (12mg/kg/day) or L-DOPA (30mg/kg/day) + Benserazide (12mg/kg/day) starting one week before the injury until sacrifice.

G. Quantification of subretinal IBA-1⁺ mononuclear phagocytes counted on the RPE at a distance of 0-500µm to CD102⁺ CNV 4, 7 and 10 days after the laser injury of 8-week-old C57BL/6J mice treated by PBS, Benserazide (12mg/kg/day) or L-DOPA (30mg/kg/day)+Benserazide (12mg/kg/day) starting one week before the laser injury until sacrifice. One-way ANOVA/Bonferroni test *P*=non-significant for each group.

H. CD102- (red) stained choroidal flatmounts 7 days after laser injury of 8-week-old C57BL/6J mice treated by PBS, Benserazide (12mg/kg/day) or L-DOPA (30mg/kg/day) + Benserazide (12mg/kg/day) starting one week before the injury until sacrifice.

I. CD102⁺ CNV area 4, 7 and 10 days after laser injury of 8-week-old C57BL/6J mice treated by PBS, Benserazide (12mg/kg/day) or L-DOPA (30mg/kg/day)+Benserazide (12mg/kg/day) starting one week before the injury until sacrifice. One-way ANOVA/Bonferroni test; p-values indicated in the figure.

SNpc: substantia nigra pars compacta; Bens: benserazide; CTL: control; MPs: mononuclear phagocytes; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. n= indicated in each column for each group. Scale bar C, F, and H: 200µm.




Fig. 2: The decarboxylation of L-DOPA to dopamine is necessary for its anti-angiogenic effect on CNV *ex-vivo* and *in vitro*

A. Quantitative Rt-PCR of mouse Dopa-decarboxylase (*Ddc*) mRNAs normalized with β -actine of fresh neuro-retina, RPE/choroid and choroid from 8-week-old C57BL/6J mice.

B. Quantitative Rt-PCR of human Dopa-decarboxylase (*Ddc*) mRNAs normalized with β -actine of fresh human RPE from donor eye and HCEC. *N.D.*: not detected.

C. Representative microphotographs of choroidal explants from 2-week-old C57BL/6J pups at day 6 after 3-day-treatment by PBS, L-DOPA (1 μ M) or Dopamine (1 μ M).

D. Quantification of vascular sprouting area between day 3 and 6 from choroidal explants prepared from 2-week-old C57BL/6J pups, and treated with Dopamine (1 μ M), Benserazide (10 μ M), L-DOPA (1 μ M) or preincubated 1 hour with Benserazide (10 μ M) before the addition of L-DOPA (1 μ M). One-way ANOVA/Bonferroni test; p-values indicated in the figure.

E. Quantification of vascular sprouting area between day 3 and 6 from choroidal explants prepared from 2-week-old C57BL/6J pups, and treated by increasing concentrations of dopamine.

F. Representative microphotographs of DAPI⁺ HCECs after a 24h-treatment with PBS, L-DOPA (1 μ M) or Dopamine (1 μ M) with or without VEGF exposure (10ng/ml). Scale bar: 200 μ m.

G. Quantification of DAPI⁺ HCECs after a 24h-treatment with PBS, L-DOPA (1 μ M) or Dopamine (1 μ M) with or without VEGF exposure (10ng/ml). One-way ANOVA/Bonferroni test; p-values indicated in the figure, PBS versus L-DOPA P =non-significant.

H: Volcano plot of differentially expressed genes (left) and scatter plot of DUSP4 read counts (right) of FACS sorted CD31⁺CD11B⁺ endothelial cells from d4 choroidal explants that had or had not been incubated with 1 μ M dopamine for 24h. The volcano plot shows the Log₂(fold-change) (x-axis) versus the significance (-Log₁₀(p-value); y-axis) of the 2276 genes with a Log₂(fold-change) greater than ± 1.0 . The vertical lines indicate the cut-off of fold-change = ± 1.0 . 13 genes (red dots) were found to be statistically upregulated by dopamine and 9 were downregulated (blue dots). The adjusted p value, indicated for the difference in DUSP4 transcription, was calculated by the Benjamini and Hochberg false discovery rate correction method.

I: Representative microphotographs and quantification of vascular sprouting area between day 3 and 6 of choroidal explants from 2-week-old C57BL/6J *Dusp4*^{+/+} and *Dusp4*^{-/-} pups. Mann-Whitney U -test; p-value indicated in the figure.

Bens: benserazide; CTL: control; HCEC: human choroidal endothelial cells; hRPE: fresh human retinal pigment epithelium; N.D.: non detected; VEGF: vascular endothelial growth factor. n=indicated in each column for each group




Fig. 3: Dopamine receptor 2 activation mediates the CNV inhibition observed under L-DOPA / decarboxylase inhibitor treatment *in vivo*

A. Quantitative Rt-PCR of dopamine receptors (DR1-DR5) mRNAs normalized with β -actine of 8-week-old C57BL/6J mouse retina 7 days after laser injury compared to control (CTL) mice. Mann-Whitney *U*-test for each DR in CNV group versus each DR in CTL group *P*=non-significant.

B. Quantitative Rt-PCR of dopamine receptors (DR1-DR5) mRNAs normalized with β -actine of 8-week-old C57BL/6J mouse choroid 7 days after laser injury compared to control mice. Mann-Whitney *U*-test for DRD2 in CNV group versus DRD2 in CTL group; p-value indicated in the figure when statistically significant.

C. Quantitative Rt-PCR of dopamine receptor 2 (DRD2) mRNAs normalized with β -actine of fresh RPE from donor eye and HCEC.

D. Representative microphotographs of choroidal explants of 2-week-old C57BL/6J pups at day 6 after 3-day-treatment by PBS, Dopamine (1 μ M) or pretreated 1 hour by Eticlopride (10 μ M) before the addition of Dopamine (1 μ M).

E. Quantification of choroidal vascular sprouting from 2-week-old C57BL/6J pups at day 6 after 3 days of treatment by PBS, Dopamine (1 μ M), pretreated for 1 hour with Eticlopride (10 μ M) before the addition of Dopamine (1 μ M), Quinpirole (10 μ M), SKF38393 (10 μ M) or PD168077 (10 μ M). One-way ANOVA/Bonferroni test; p-values indicated in the figure, PBS versus SKF38393 and PD168077 *P*=non-significant.

F. IBA-1- (green) and CD102- (red) stained choroidal flatmounts 7 days after laser injury of 8-week-old C57BL/6J mice treated by PBS or Quinpirole (5mg/kg) starting one week before the injury until sacrifice. Scale bar: 200 μ m.

G. Quantification of subretinal IBA-1⁺ mononuclear phagocytes counted on the RPE at a distance of 0-500 μ m to CD102⁺ CNV 7 days after the laser injury of 8-week-old C57BL/6J mice and treated by PBS, L-DOPA (30mg/kg)+Benserazide (12mg/kg), L-DOPA (30mg/kg)+Benserazide (12mg/kg)+Eticlopride (1mg/kg) or Quinpirole (5mg/kg) starting one week before the injury until sacrifice. One-way ANOVA/Bonferroni test *P*=non significant for each group.

H. CD102⁺ CNV area 7 days after laser injury of 8-week-old C57BL/6J mice and treated by PBS, L-DOPA (30mg/kg)+Benserazide (12mg/kg), L-DOPA (30mg/kg)+Benserazide

(12mg/kg)+Eticlopride (1mg/kg) or Quinpirole (5mg/kg) starting one week before the injury until sacrifice. One-way ANOVA/Bonferroni test; p-values indicated in the figure.

Bens: benserazide; CTL: control; HCEC: human choroidal endothelial cells; hRPE: fresh human retinal pigment epithelium; MPs: mononuclear phagocytes; RPE: retinal pigment epithelium. n=indicated in each column for each group




Fig. 4: Incidence of nAMD and frequency of anti-VEGF injections are reduced in PD patients treated with L-DOPA/DDI and DRD2 agonists

A–C. Number of patients (Y axis) receiving the first IVT as a function of age (X axis) of (A) the 193 512 nAMD control patients, (B) of the 5650 parkinsonian nAMD patients receiving DRD2 agonists and (C) of the 1570 parkinsonian nAMD patients receiving L-DOPA/DDI therapy. The mean age for each group is indicated by the dotted line.

D. Distribution curves normalized for each group (percentage of cases of the group) of patients receiving the first IVT as a function of age (ANOVA test: control nAMD patients versus DRD2 agonists or L-DOPA/DDI nAMD patients $p<0.0001$).

E–F. Correlation of (E) DRD2 agonist- or (F) L-DOPA/DDI-treatment group with the number of IVTs during the second year of nAMD treatment (anti-VEGF-naive nAMD patients in France are generally initiated with a fixed proactive regimen during the first year and the treatment regimen is only then adapted to pathology activity) (univariate linear generalized model: control nAMD patients versus DRD2 agonists nAMD patients only $p<0.0001$ (E) or versus nAMD patients on L-DOPA/DDI nAMD patients only $p=0.02$) (F)).

DDI: DOPA-decarboxylase inhibitor; IVT: intravitreal injection; nAMD: neovascular age-related macular degeneration; VEGF: vascular endothelial growth factor.

Table 1: characteristics of study participants

	nAMD patients w/o dopaminergic treatment (Control) N=193 512	Anti-Parkinsonian treatment	
		L-DOPA/DDI N=1 570	DRD2 agonist N=5 650
Gender, female, %	66.8%	62.2%	71.5%
Co-morbidities, %			
Diabetes	12.7%	12.6%	11.4%
Dyslipidemia	59.2%	56.3%	61.6%
High blood pressure	83.2%	88.0%	87.0%
Chronic alcoholism	2,0%	1,5%	1,9%
Smoking	4,1%	2,6%	4,0%
Obesity	8,7%	8,3%	9,7%
Age at first injection, mean (SD), years	79.4 (8.1)	83.3 (5.6)	81.4 (7.0)
Number of injections, mean (SD)			
1 st year	4.9 (2.8)	4.5 (2.6)	4.9 (2.9)
2 nd year	2.5 (3.1)	1.9 (2.7)	2.5 (3.1)
Treatment daily dose	-		
Median [IQR], mg		199.1 [67.3-334.7]	5.0 [0.6-35.3]
Mean (SD)		249.0 (217.5)	20.4 (29.7)

DDI: DOPA-decarboxylase inhibitor; DRD2: Dopamine receptor D2; IQR: interquartile range; nAMD neovascular age-related macular degeneration; SD: standard deviation.